tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market
Advertisement

SAB Biotherapeutics (SABS) AI Stock Analysis

Compare
172 Followers

Top Page

SABS

SAB Biotherapeutics

(NASDAQ:SABS)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 4o)
Rating:50Neutral
Price Target:
$3.00
▼(-0.99% Downside)
The overall stock score is primarily impacted by weak financial performance and poor valuation metrics. While technical analysis shows some positive momentum, the financial challenges and valuation concerns weigh heavily on the stock's attractiveness.
Positive Factors
Proprietary Technology
The proprietary DiversitAb platform provides a competitive advantage by enabling the production of large quantities of human antibodies, potentially leading to effective treatments for infectious diseases and immune disorders.
Strategic Partnerships
Strategic partnerships and licensing agreements with pharmaceutical companies and government agencies enhance revenue potential and support the development and commercialization of antibody-based therapies.
Government Contracts
Government contracts and grants provide a stable revenue source, supporting ongoing research and development efforts and reducing reliance on market-driven revenue.
Negative Factors
Revenue Decline
A significant decline in revenue indicates challenges in market demand or product adoption, potentially impacting long-term growth and sustainability.
Negative Cash Flow
Persistent negative cash flow suggests difficulties in funding operations and maintaining liquidity, posing risks to financial stability and operational continuity.
High Debt Levels
High debt levels can strain financial resources and limit strategic flexibility, potentially affecting the company's ability to invest in growth opportunities.

SAB Biotherapeutics (SABS) vs. SPDR S&P 500 ETF (SPY)

SAB Biotherapeutics Business Overview & Revenue Model

Company DescriptionSAB Biotherapeutics (SABS) is a biotechnology company focused on developing and commercializing therapeutic products derived from its proprietary platform utilizing immunoglobulin-producing animals. The company operates primarily in the biopharmaceutical sector, specializing in the production of polyclonal antibodies for the treatment of various diseases, including infectious diseases, autoimmune disorders, and cancer. SAB's core products include SAB-176, a therapeutic candidate for COVID-19, and other antibody therapies in various stages of development.
How the Company Makes MoneySAB Biotherapeutics generates revenue through multiple channels, including government and private sector grants, partnerships with pharmaceutical companies for the development and commercialization of its therapeutic products, and potential product sales once therapies are approved and brought to market. The company has established significant collaborations with organizations such as the U.S. government for funding and support in developing treatments, which contribute to its revenue streams. Additionally, SAB may earn royalties or milestone payments from partners as products progress through clinical trials and achieve regulatory approvals.

SAB Biotherapeutics Financial Statement Overview

Summary
SAB Biotherapeutics faces significant financial challenges, highlighted by declining revenues, persistent losses, and cash flow difficulties. Despite a reasonable equity ratio, the high debt-to-equity ratio and negative net profit margins indicate ongoing financial instability.
Income Statement
40
Negative
SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.
Balance Sheet
55
Neutral
The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.
Cash Flow
30
Negative
SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue-410.001.32M2.24M23.90M60.88M55.24M
Gross Profit-3.27M-3.47M-1.51M20.61M59.22M55.24M
EBITDA-33.92M-28.99M-38.13M-15.12M-15.20M21.14M
Net Income-37.06M-34.10M-42.19M-18.74M-17.14M20.12M
Balance Sheet
Total Assets30.13M44.20M83.94M50.90M79.37M56.54M
Cash, Cash Equivalents and Short-Term Investments5.71M20.76M56.57M15.05M33.21M12.61M
Total Debt6.42M4.67M5.91M5.93M8.52M8.13M
Total Liabilities18.11M18.23M26.64M19.85M40.82M17.53M
Stockholders Equity12.02M25.97M57.30M31.06M38.55M39.01M
Cash Flow
Free Cash Flow-38.26M-34.63M-25.32M-7.19M-7.19M-2.73M
Operating Cash Flow-38.11M-34.29M-25.12M3.76M3.76M10.00M
Investing Cash Flow18.05M-11.96M-152.70K-10.94M-10.94M-12.72M
Financing Cash Flow-805.00K-1.17M66.77M1.05M34.12M8.98M

SAB Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price3.03
Price Trends
50DMA
2.29
Positive
100DMA
2.21
Positive
200DMA
2.07
Positive
Market Momentum
MACD
0.20
Negative
RSI
68.19
Neutral
STOCH
91.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Positive. The current price of 3.03 is above the 20-day moving average (MA) of 2.42, above the 50-day MA of 2.29, and above the 200-day MA of 2.07, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 68.19 is Neutral, neither overbought nor oversold. The STOCH value of 91.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SABS.

SAB Biotherapeutics Risk Analysis

SAB Biotherapeutics disclosed 80 risk factors in its most recent earnings report. SAB Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

SAB Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
$31.55M-0.76-127.48%-95.87%35.25%
43
Neutral
$20.58M-1.05-63.84%12.95%
40
Underperform
$13.90M-67.47%9.63%
36
Underperform
$24.62M-0.36-104.07%1.66%
35
Underperform
$23.06M-66.12%154.52%47.84%
31
Underperform
$19.83M-0.30-183.72%20.28%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SABS
SAB Biotherapeutics
3.03
0.11
3.77%
LSTA
Lisata Therapeutics
2.35
-0.53
-18.40%
LPTX
Leap Therapeutics
0.48
-3.67
-88.43%
NXTC
NextCure
9.20
-7.12
-43.63%
SNSE
Sensei Biotherapeutics
10.56
-1.32
-11.11%
RLYB
Rallybio
0.61
-0.43
-41.35%

SAB Biotherapeutics Corporate Events

Executive/Board ChangesPrivate Placements and Financing
SAB Biotherapeutics Board Members Resign in Agreement
Neutral
Sep 30, 2025

On September 30, 2025, Christine Hamilton and Jeffrey Spragens resigned from the Board of Directors of SAB Biotherapeutics, Inc., reducing the Board’s size from 11 to nine members. This change was in line with an agreement with RA Capital Healthcare Fund, L.P., following a private placement of securities in July 2025. The resignations were not due to any disagreements with the company, and the Board expressed gratitude for their service.

The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

Regulatory Filings and ComplianceShareholder Meetings
SAB Biotherapeutics Approves Equity Plan Amendments
Neutral
Sep 26, 2025

On September 26, 2025, SAB Biotherapeutics held a special meeting where stockholders approved amendments to the company’s 2021 Omnibus Equity Incentive Plan, significantly increasing the number of shares available for participants. Additionally, stockholders approved the potential issuance of shares exceeding 19.99% of the company’s outstanding stock upon conversion of Series B Convertible Preferred Stock, which may be considered a ‘change of control’ under Nasdaq rules.

The most recent analyst rating on (SABS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on SAB Biotherapeutics stock, see the SABS Stock Forecast page.

SAB Biotherapeutics Reports Increased Losses Amid Funding Boost
Aug 8, 2025

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. In its latest earnings report, SAB Biotherapeutics disclosed a net loss of $15.3 million for the first half of 2025, compared to a $12.4 million loss in the same period last year, with no revenue generated during this time. The company’s operating expenses were primarily driven by research and development costs, which totaled $14.7 million, and general and administrative expenses of $5.9 million. Despite the financial losses, the company successfully raised approximately $175 million through a private placement offering to fund its ongoing research and development activities, including the Phase 2b SAFEGUARD study of its lead candidate, SAB-142. Looking ahead, SAB Biotherapeutics anticipates continued financial challenges as it progresses its product candidates through development and regulatory approval processes, with management actively seeking additional funding to support its long-term strategic goals.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 21, 2025